3-Butan-2-yl-5-propan-2-yl-1,2,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-Butan-2-yl-5-propan-2-yl-1,2,4-oxadiazole
• 英文别名: 3-butan-2-yl-5-propan-2-yl-1,2,4-oxadiazole
• 化学式: C₉H₁₆N₂O
• 分子量: 168.24
• InChiKey: HGTXHWDUUZFVSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20190284182A1

  公开（公告）日：2019-09-19

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物和组合物。
• PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：US20200048238A1

  公开（公告）日：2020-02-13

  Compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.

  本发明涉及式(I)的化合物，其定义如下，以及制备它们的方法，包括它们的杀虫剂、杀螨剂、杀软体动物剂和杀线虫剂组合物，以及使用它们来打击和控制昆虫、螨虫、软体动物和线虫等害虫的方法。
• METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF
  申请人：Heffernan Michele L. R.

  公开号：US20140221332A1

  公开（公告）日：2014-08-07

  Compounds that modulate GluR5 activity and methods of using the same are disclosed.

  本发明揭示了调节GluR5活性的化合物及其使用方法。
• Inhibitors of plasma kallikrein and uses thereof
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US10730874B2

  公开（公告）日：2020-08-04

  The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

  本发明提供了可用作血浆钙激酶抑制剂并表现出理想特性的化合物及其组合物。
• Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119
  申请人：PRAMANA PHARMACEUTICALS INC.

  公开号：US11358956B2

  公开（公告）日：2022-06-14

  There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6′ and X6″ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7′ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7′ together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I)

  提供了具有式(I)的化合物，其中：X1和X2选自O、S、SO和SO2的某些组合；X3选自CH、CF和N；X4选自CH和N；X6、X6′和X6″选自H、卤素和某些烷基、卤代烷基、烷氧基、羟基烷基和酰胺基团；X7和X7′选自H、卤素和某些烷基、卤代烷基、烷氧基、羟基烷基、氨基烷基和酰胺基团，或X7和X7′共同形成环烷基或杂环；A选自某些任选取代的烷氧基、哌嗪基和吡咯烷基团。还提供了包含这些化合物的组合物，以及与之相关的用途/方法，包括治疗与 GPR119 失调、2 型糖尿病和相关代谢紊乱有关的疾病和病症。(I)